Explore

Trendline Trendline
AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted
Trendline Trendline
Capricor and Replimune Face Uncertain FDA Advisory Committee Outcomes

Capricor and Replimune Face Uncertain FDA Advisory Committee Outcomes

Capricor and Replimune Face Uncertain FDA Advisory Committee Outcomes
Trendline Trendline
Agenus to Announce Q2 2026 Financial Results and Development Update

Agenus to Announce Q2 2026 Financial Results and Development Update

Agenus to Announce Q2 2026 Financial Results and Development Update
Trendline Trendline
Caribou Biosciences Advances CRISPR Gene Editing Trials for Cancer Therapies

Caribou Biosciences Advances CRISPR Gene Editing Trials for Cancer Therapies

Caribou Biosciences Advances CRISPR Gene Editing Trials for Cancer Therapies
Trendline Trendline
Incyte Discontinues Early-Stage Cancer Drug to Focus on Advanced Therapies

Incyte Discontinues Early-Stage Cancer Drug to Focus on Advanced Therapies

Incyte Discontinues Early-Stage Cancer Drug to Focus on Advanced Therapies
Rapid Read Rapid Read
Pancreatic Cancer Drug Daraxonrasib Extends Survival in Phase 3 Trial

Pancreatic Cancer Drug Daraxonrasib Extends Survival in Phase 3 Trial

A phase 3 trial has shown that the drug daraxonrasib nearly doubles the median overall survival for patients with previously treated metastatic pancreatic cancer. The trial involved 500 patients and extended survival to 13.2 months compared to 6.7 months with standard chemotherapy. Despite not being a cure, the drug represents a significant advancement in treating a cancer with a high mortality rate. Daraxonrasib targets the KRAS gene, which is mutated in over 90% of pancreatic tumors. The drug is not yet approved, but an expanded access protocol allows certain patients to receive it outside of clinical trials.
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Rapid Read Rapid Read
ProMIS Neurosciences to Present Interim Data on Alzheimer's Treatment

ProMIS Neurosciences to Present Interim Data on Alzheimer's Treatment

ProMIS Neurosciences is set to host a webinar to discuss the six-month blinded interim data from its PRECISE-AD Phase 1b trial of PMN310, a treatment for Alzheimer's disease. The trial focuses on evaluating the safety, tolerability, and pharmacokinetics of PMN310 in patients with early Alzheimer's. The analysis will include aggregate safety data and trends in select biomarkers. PMN310 is designed to target toxic oligomers of amyloid-beta, which are believed to be early drivers of Alzheimer's, while avoiding amyloid plaques. The trial has enrolled 144 participants and aims to provide insights into the effects of PMN310 on biomarkers and clinical outcomes.
Rapid Read Rapid Read
FDA Advisory Committee Recommends Lifting Regulations on Experimental Peptides Amidst Safety Concerns

FDA Advisory Committee Recommends Lifting Regulations on Experimental Peptides Amidst Safety Concerns

A U.S. drug advisory committee has recommended that the FDA lift regulations on several experimental peptides, allowing select pharmacies to manufacture and doctors to prescribe them. This decision comes despite the lack of large-scale human trials to support the safety and efficacy of these compounds. Peptides, which are short chains of amino acids, are being marketed for a variety of health benefits, including anti-aging and injury healing. The unregulated market for these peptides is estimated to be worth between $100 million and $3 billion. The committee's recommendation aims to mitigate risks associated with purchasing these products from unregulated sources, but it also raises concerns about the message it sends regarding their safety.
Trendline Trendline
MapLight's Schizophrenia Drug Faces Challenges After Mixed Phase 2 Trial Results

MapLight's Schizophrenia Drug Faces Challenges After Mixed Phase 2 Trial Results

MapLight's Schizophrenia Drug Faces Challenges After Mixed Phase 2 Trial Results
Trendline Trendline
Arrowhead Pharmaceuticals Completes Enrollment in Phase 3 Study for Zodasiran Targeting Rare Cholesterol Disorder

Arrowhead Pharmaceuticals Completes Enrollment in Phase 3 Study for Zodasiran Targeting Rare Cholesterol Disorder

Arrowhead Pharmaceuticals Completes Enrollment in Phase 3 Study for Zodasiran Targeting Rare Cholesterol Disorder
Rapid Read Rapid Read
Early-Phase Trial of Cevostamab Shows Promise for Multiple Myeloma Treatment

Early-Phase Trial of Cevostamab Shows Promise for Multiple Myeloma Treatment

A phase I clinical trial has shown that the investigational bispecific antibody cevostamab can reduce cancer in over 40% of patients with relapsed or refractory multiple myeloma. The trial, involving 324 patients, demonstrated a median duration of response of 11.2 months. Cevostamab targets the FcRH5 protein on plasma cells, activating T cells to attack myeloma. The study, published in Nature Medicine, highlights cevostamab's potential as a new treatment option, especially for patients who have undergone multiple prior treatments. The trial also explored a fixed-duration treatment approach, contrasting with indefinite treatment regimens.